Abcam Plc (LON:ABC) Stock Rating Reaffirmed by Panmure Gordon
Other analysts have also issued reports about the stock. Numis Securities Ltd upgraded shares of Abcam Plc to an add rating and set a GBX 912 ($11.84) price objective on the stock in a report on Tuesday, April 4th. Berenberg Bank started coverage on shares of Abcam Plc in a report on Tuesday, June 27th. They issued a buy rating and a GBX 1,100 ($14.28) price objective on the stock. Finally, Stifel Nicolaus restated a hold rating and issued a GBX 890 ($11.55) price objective on shares of Abcam Plc in a report on Tuesday, May 2nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. The stock presently has a consensus rating of Hold and a consensus price target of GBX 900 ($11.68).
Abcam Plc (LON:ABC) traded up 1.03% on Thursday, hitting GBX 1081.00. 224,069 shares of the stock were exchanged. The firm’s market cap is GBX 2.19 billion. Abcam Plc has a 52-week low of GBX 714.00 and a 52-week high of GBX 1,090.00. The stock’s 50 day moving average price is GBX 1,000.49 and its 200 day moving average price is GBX 922.78.
In other news, insider Mara G. Aspinall bought 2,700 shares of the company’s stock in a transaction on Monday, June 5th. The stock was bought at an average cost of GBX 979 ($12.71) per share, with a total value of £26,433 ($34,315.20).
Abcam Plc Company Profile
Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company’s purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways.
Receive News & Stock Ratings for Abcam Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam Plc and related stocks with our FREE daily email newsletter.